199 related articles for article (PubMed ID: 30852622)
1. Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.
Koster BD; Santegoets SJAM; Harting J; Baars A; van Ham SM; Scheper RJ; Hooijberg E; de Gruijl TD; van den Eertwegh AJM
Cancer Immunol Immunother; 2019 Jun; 68(6):1025-1035. PubMed ID: 30852622
[TBL] [Abstract][Full Text] [Related]
2. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
3. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group.
Dillman RO; Wiemann M; Nayak SK; DeLeon C; Hood K; DePriest C
J Immunother; 2003; 26(4):367-73. PubMed ID: 12843799
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.
Oosterwijk-Wakka JC; Tiemessen DM; Bleumer I; de Vries IJ; Jongmans W; Adema GJ; Debruyne FM; de Mulder PH; Oosterwijk E; Mulders PF
J Immunother; 2002; 25(6):500-8. PubMed ID: 12439347
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.
Schwaab T; Schwarzer A; Wolf B; Crocenzi TS; Seigne JD; Crosby NA; Cole BF; Fisher JL; Uhlenhake JC; Mellinger D; Foster C; Szczepiorkowski ZM; Webber SM; Schned AR; Harris RD; Barth RJ; Heaney JA; Noelle RJ; Ernstoff MS
Clin Cancer Res; 2009 Aug; 15(15):4986-92. PubMed ID: 19622576
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
10. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma.
Gitlitz BJ; Belldegrun AS; Zisman A; Chao DH; Pantuck AJ; Hinkel A; Mulders P; Moldawer N; Tso CL; Figlin RA
J Immunother; 2003; 26(5):412-9. PubMed ID: 12973030
[TBL] [Abstract][Full Text] [Related]
11. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.
Simons JW; Jaffee EM; Weber CE; Levitsky HI; Nelson WG; Carducci MA; Lazenby AJ; Cohen LK; Finn CC; Clift SM; Hauda KM; Beck LA; Leiferman KM; Owens AH; Piantadosi S; Dranoff G; Mulligan RC; Pardoll DM; Marshall FF
Cancer Res; 1997 Apr; 57(8):1537-46. PubMed ID: 9108457
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma.
Märten A; Renoth S; Heinicke T; Albers P; Pauli A; Mey U; Caspari R; Flieger D; Hanfland P; Von Ruecker A; Eis-Hübinger AM; Müller S; Schwaner I; Lohmann U; Heylmann G; Sauerbruch T; Schmidt-Wolf IG
Hum Gene Ther; 2003 Mar; 14(5):483-94. PubMed ID: 12691613
[TBL] [Abstract][Full Text] [Related]
13. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.
Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A
J Immunother Cancer; 2017; 5():52. PubMed ID: 28642820
[TBL] [Abstract][Full Text] [Related]
14. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.
Höltl L; Ramoner R; Zelle-Rieser C; Gander H; Putz T; Papesh C; Nussbaumer W; Falkensammer C; Bartsch G; Thurnher M
Cancer Immunol Immunother; 2005 Jul; 54(7):663-70. PubMed ID: 15918076
[TBL] [Abstract][Full Text] [Related]
18. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.
Avigan DE; Vasir B; George DJ; Oh WK; Atkins MB; McDermott DF; Kantoff PW; Figlin RA; Vasconcelles MJ; Xu Y; Kufe D; Bukowski RM
J Immunother; 2007 Oct; 30(7):749-61. PubMed ID: 17893567
[TBL] [Abstract][Full Text] [Related]
19. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
